IRIS
CONTEDUCA, VINCENZA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.055
EU - Europa 2.828
AS - Asia 2.552
SA - Sud America 1.092
Continente sconosciuto - Info sul continente non disponibili 599
AF - Africa 66
OC - Oceania 4
Totale 10.196
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.929
IE - Irlanda 1.084
SG - Singapore 1.010
BR - Brasile 893
RU - Federazione Russa 699
HK - Hong Kong 437
VN - Vietnam 435
CN - Cina 341
SE - Svezia 272
IT - Italia 235
FR - Francia 165
DE - Germania 110
BD - Bangladesh 75
AR - Argentina 73
GB - Regno Unito 58
CA - Canada 49
IN - India 48
FI - Finlandia 47
MX - Messico 44
UA - Ucraina 38
EC - Ecuador 35
ID - Indonesia 33
CO - Colombia 27
AE - Emirati Arabi Uniti 24
IQ - Iraq 24
NL - Olanda 23
TR - Turchia 23
ZA - Sudafrica 19
PL - Polonia 18
AT - Austria 15
ES - Italia 15
PY - Paraguay 15
VE - Venezuela 14
JP - Giappone 12
CL - Cile 11
PE - Perù 11
UZ - Uzbekistan 11
MA - Marocco 10
PK - Pakistan 10
SA - Arabia Saudita 10
UY - Uruguay 10
DO - Repubblica Dominicana 9
EG - Egitto 8
NP - Nepal 8
BE - Belgio 7
NO - Norvegia 6
PH - Filippine 6
CR - Costa Rica 5
DZ - Algeria 5
LT - Lituania 5
OM - Oman 5
SK - Slovacchia (Repubblica Slovacca) 5
SY - Repubblica araba siriana 5
AZ - Azerbaigian 4
ET - Etiopia 4
JM - Giamaica 4
KE - Kenya 4
LB - Libano 4
TN - Tunisia 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AU - Australia 3
GR - Grecia 3
JO - Giordania 3
MD - Moldavia 3
MY - Malesia 3
NI - Nicaragua 3
RO - Romania 3
TW - Taiwan 3
AL - Albania 2
BH - Bahrain 2
BN - Brunei Darussalam 2
BO - Bolivia 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
CZ - Repubblica Ceca 2
GE - Georgia 2
GT - Guatemala 2
HN - Honduras 2
HR - Croazia 2
IL - Israele 2
KZ - Kazakistan 2
LY - Libia 2
MK - Macedonia 2
PR - Porto Rico 2
SN - Senegal 2
TT - Trinidad e Tobago 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
BB - Barbados 1
BZ - Belize 1
CH - Svizzera 1
CY - Cipro 1
DK - Danimarca 1
GA - Gabon 1
GH - Ghana 1
GP - Guadalupe 1
HU - Ungheria 1
KH - Cambogia 1
KI - Kiribati 1
KW - Kuwait 1
Totale 9.588
Salva come PNG Salva come JPEG
Città #
Dublin 1.082
San Jose 837
Hong Kong 435
Singapore 414
Ashburn 240
Nyköping 208
Santa Clara 171
Ho Chi Minh City 165
Council Bluffs 162
Chandler 146
Lauterbourg 137
Princeton 128
Wilmington 127
Dallas 118
Hanoi 84
São Paulo 82
Beijing 73
The Dalles 58
Munich 51
Columbus 40
Moscow 34
New York 32
Helsinki 26
Des Moines 25
Los Angeles 25
Belo Horizonte 23
Da Nang 21
Rio de Janeiro 21
Nuremberg 20
Jacksonville 18
London 18
Brasília 17
Quito 17
Shanghai 17
Brooklyn 16
Milan 16
Turku 16
Warsaw 15
Chicago 14
Mexico City 14
Curitiba 13
Guarulhos 13
Rome 13
Thái Bình 13
Buenos Aires 12
Frankfurt am Main 12
Phoenix 12
Porto Alegre 12
Atlanta 11
Bari 11
Guangzhou 11
Hillsboro 11
Martina Franca 11
Nanjing 11
Orem 11
Salvador 11
Can Tho 10
Haiphong 10
Ninh Bình 10
Nocera Inferiore 10
Tashkent 10
Toronto 10
Biên Hòa 9
Campinas 9
Chennai 9
Dhaka 9
Johannesburg 9
Norwalk 9
Ribeirão Preto 9
San Francisco 9
Tokyo 9
Trento 9
Goiânia 8
Montevideo 8
Thái Nguyên 8
Wuhan 8
Ankara 7
Boston 7
Buffalo 7
Caxias do Sul 7
Dearborn 7
Formosa 7
Fortaleza 7
Hortolândia 7
Hải Dương 7
Itaquaquecetuba 7
Lima 7
Lấp Vò 7
Madrid 7
Montreal 7
Mumbai 7
Potenza 7
Stockholm 7
Amsterdam 6
Brussels 6
Canoas 6
Garden City 6
Guayaquil 6
Manaus 6
Manchester 6
Totale 5.694
Salva come PNG Salva come JPEG
Nome #
Pathophysiology of HCV-Related cryoglobulinemic vasculitis: molecular, immunological and clinical analysis 172
18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide 118
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists. 105
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis 102
Adenosine A3 receptor antagonists as anti-tumor treatment in human prostate cancer: an in vitro study 101
T cell receptor variable β gene repertoire in liver and peripheral blood lymphocytes of chronically hepatitis C virus-infected patients with and without mixed cryoglobulinaemia. 96
Axitinib after Sunitinib in metastatic renal cancer: Preliminary results from Italian "Real-World" SAX Study 96
Pancreatic Enzyme Replacement and Nutritional Support With nab-Paclitaxel-based First-Line Chemotherapy Regimens in Metastatic Pancreatic Cancer 95
Circulating Tumor DNA: A New Research Frontier in Urological Oncology from Localized to Metastatic Disease 94
Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent Differentiation 88
Anogenital lichen sclerosus et atrophicus lesions in a case series of cancer patients on immunotherapy. 88
B-cell frequency in hepatitis C virus-related mixed cryoglobulinemia 87
Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience 86
Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide. 85
Androgen receptor signaling pathways as a target for breast cancer treatment 85
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. 85
Role of the receptor for the globular domain of C1q protein in the pathogenesis of hepatitis C virus-related cryoglobulin vascular damage 85
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: A multi-institution correlative biomarker study 84
Association among metabolic syndrome, inflammation, and survival in prostate cancer 84
Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patients 83
Serum Mass Spectrometry Proteomics and Protein Set Identification in Response to FOLFOX-4 in Drug-Resistant Ovarian Carcinoma 82
Clinical features of neuroendocrine prostate cancer 80
Androgen receptor, PARP signaling, and tumor microenvironment: the ‘perfect triad’ in prostate cancer? 80
Changing metastatic patterns associate with dynamics of circulating tumor DNA in metastatic castration-resistant prostate cancer 79
Epigenetics in prostate cancer: clinical implications 78
Advanced low grade serous ovarian cancer: A retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers 77
Impact of Somatic DNA Repair Mutations on the Clinical Outcomes of Bone Metastases from Castration-Resistant Prostate Cancer 77
Immunogenomic profiles associated with response to life-prolonging agents in prostate cancer 77
Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial. 77
Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test 77
AR copy number and AR signaling-directed therapies in castration-resistant prostate cancer 77
A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide 77
Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies 75
Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents 75
H. pylori infection and gastric cancer: State of the art (Review) 75
Barrett's esophagus and esophageal cancer: An overview 75
N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer 75
Interleukin 28B Gene Polymorphisms in Hepatitis C Virus-related Cryoglobulinemic Vasculitis 73
An update on our ability to monitor castration-resistant prostate cancer dynamics with cell-free DNA. 73
Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer 73
Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis. 73
Concomitant Administration of VEGFR Tyrosine Kinase and Proton Pump Inhibitors May Impair Clinical Outcome of Patients With Metastatic Renal Cancer 72
Association Between Early PSA Increase and Clinical Outcome in Patients Treated with Enzalutamide for Metastatic Castration Resistant Prostate Cancer 72
Metabolic syndrome as a peculiar target for management of prostate cancer patients 72
Biological Evolution of Castration-resistant Prostate Cancer 72
Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. 71
Barrett's esophagus and esophageal cancer: An overview 71
Plasma AR and abiraterone-resistant prostate cancer 71
The prostatic inflammation score and risk of biochemical recurrence following radical prostatectomy 70
A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma. 70
Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone 70
Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial. 69
Adherence to Oral Treatments in Older Patients with Advanced Prostate Cancer, the ADHERE Study: A Prospective Trial of the Meet-URO Network 68
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care 67
Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide 67
Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer 67
New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer. 66
Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis 66
TRAP1 modulates mitochondrial biogenesis via PGC-1α/TFAM signalling pathway in colorectal cancer cells 65
Plasma androgen receptor and serum chromogranin A in advanced prostate cancer 65
Re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724–31 65
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study 64
Melphalan as a Promising Treatment for BRCA-Related Ovarian Carcinoma. 64
Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide 64
BRCA2-Associated Prostate Cancer in a Patient With Spinal and Bulbar Muscular Atrophy 64
Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone 63
Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients. 63
The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment. 62
Impact of Candidate Genetic Polymorphisms in Prostate Cancer: An Overview 62
Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer 61
Increased serum levels of the chemokine CXCL13 and up-regulation of its gene expression are distinctive features of HCV-related cryoglobulinemia and correlate with active cutaneous vasculitis 60
The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives. 60
Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis 60
Validation of a Combined Prognostic Score Using Plasma Tumor DNA and Clinical Features in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Taxanes 60
The 5-WS of targeting DNA-damage repair (DDR) pathways in prostate cancer 59
PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer 59
Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis 58
Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide 57
The potential use of urine cell free DNA as a marker for cancer 57
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer 56
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer 56
Circulating myeloid-derived suppressor cells and survival in prostate cancer patients: systematic review and meta-analysis 56
Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. 55
High Neutrophil-to-lymphocyte Ratio Persistent During First-line Chemotherapy Predicts Poor Clinical Outcome in Patients with Advanced Urothelial Cancer 55
Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: Results of the Italian Named Patient Programme 54
Impact of cryoglobulinemic syndrome on the outcome of chronic hepatitis C virus infection: A 15-year prospective study 54
Cell-free DNA as a diagnostic marker for cancer: Current insights 54
Molecular mechanisms of resistance in testicular germ cell tumors - Clinical implications 54
Prognostic Implications of Blood Immune-Cell Composition in Metastatic Castration-Resistant Prostate Cancer 54
Pharmacological treatment landscape of non-metastatic hormone-sensitive prostate cancer: A narrative review on behalf of the meet-URO Group 53
Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib 53
The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: An unresolved controversy 53
Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib 53
Safety and Clinical Outcomes of Abiraterone Acetate after Docetaxel in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme 53
Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone 53
Systemic immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abiraterone 53
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study. 53
Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer 52
Pegylated interferon-α, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: A long-term study 52
Longitudinal assessment of plasma androgen receptor copy number predicts overall survival in subsequent treatment lines in castration-resistant prostate cancer: analysis from a prospective trial 51
Totale 7.124
Salva come PNG Salva come JPEG
Categoria #
all - tutte 78.367
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 78.367
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022852 0 2 3 1 371 15 25 50 102 104 17 162
2022/20231.723 186 31 86 25 47 109 3 71 1.117 15 19 14
2023/2024222 11 19 11 19 26 77 1 21 8 7 1 21
2024/20252.162 103 68 11 30 61 257 223 100 591 206 247 265
2025/20264.690 245 458 619 1.028 142 121 778 441 372 286 133 67
2026/2027404 147 257 0 0 0 0 0 0 0 0 0 0
Totale 10.196